Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

sections

Category list : All-Wales Medicines Strategy Group

Sort by: Newest first Oldest first A-Z Z-A

  • August 2015: AWMSG approvals Subscription

    8 SEP 2015 11:07

    The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG): brimonidine gel for treating the symptoms of moderate-to-severe, persistent facial erythema associated with rosacea; Rezolsta (darunavir and cobicistat) for use in combination with other antiretroviral medicines to treat human immunodeficiency virus-1 infection in adults; magnesium aspartate dihydrate for treating and preventing magnesium deficiency in patients aged two ...

  • AWMSG medicines approvals Subscription

    27 JUL 2015 9:53

    The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG): Darunavir, in combination with other antiretrovirals, for treating human immunodeficiency virus-1 infection in children aged at least three years and weighing 15kg and over; peginterferon beta-1a for treating adults with relapsing-remitting multiple sclerosis; regorafenib for treating adults with unresectable or metastatic gastrointestinal stromal tumours who progressed ...

  • July 2015: AWMSG approvals Subscription

    10 JUL 2015 13:04

    The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG): Fostair (beclometasone/formoterol; Chiesi) inhaler for patients with chronic obstructive pulmonary disease, and Adcetris (brentuximab; Takeda) for adults with relapsed or refractory CD30+ Hodgkin lymphoma who have undergone an autologous stem cell transplant or following at least two other therapies. The drug is not recommended for treating systemic anaplastic large cell ...

  • June 2015 AWMSG approvals Subscription

    15 JUN 2015 14:54

    Adalimumab (Humira; AbbVie) can be prescribed in NHS Wales to treat active, enthesitis-related arthritis in patients aged six years and older, following its use being approved by the All Wales Medicines Strategy Group (AWMSG). The group has not recommended dapagliflozin (Forxgia; Bristol-Myers Squibb) as monotherapy for type 2 diabetes or aflibercept (Zaltrap; Sanofi) for metastatic colorectal cancer (in combination with irinotecan, ...

  • AWMSG medicines approvals Subscription

    27 MAY 2015 13:40

    The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG): bedaquiline for pulmonary multidrug‑resistant tuberculosis in adult patients as part of an appropriate combination regimen; daclatasvir for chronic hepatitis C virus infection in adults with significant fibrosis or compensated cirrhosis (as part of combination treatment); defibrotide for severe hepatic veno-occlusive disease alongside haematopoietic stem-cell transplantation ...

  • AWMSG medicines approvals Subscription

    13 MAR 2015 16:46

    Infliximab biosimilars Inflectra (Hospira) and Remsima (Celltrion) have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG). Both can be used for any licensed indication in accordance with AWMSG or National Institute for Health and Care Excellence guidance and should be prescribed by brand. The group has also approved lurasidone (Latuda; Sunovion) to treat adults with schizophrenia and Anoro Ellipta (umeclidinium and vilanterol; GlaxoSmithKline) to relieve ...

  • Cabozantinib and follitropin alfa recommended in Wales Subscription

    6 FEB 2015 9:35

    Cabozantinib has been recommended for use by the All Wales Medicines Strategy Group for progressive, unresectable, locally advanced or metastatic medullary thyroid carcinoma. The group has also approved follitropin alfa for use in NHS Wales to stimulate follicular development in women: With anovulation unresponsive to clomiphene Undergoing superovulation for assisted reproduction With severe luteinising hormone and follicle-stimulating hormone deficiency It ...

  • AWMSG medicines decisions Subscription

    16 JAN 2015 11:12

    The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG) in January 2015: leuprorelin acetate as neoadjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced prostate cancer; umeclidinium (Incruse) and olodaterol (Striverdi Respimat) to relieve symptoms in chronic obstructive pulmonary disease; ponatinib to treat chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia, ...

  • Alogliptin approved for use in Wales Subscription

    6 NOV 2014 17:11

    The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG): alogliptin, in combination with metformin or a sulphonylurea, to treat adults with type 2 diabetes (Vipdomet — a combination tablet containing metformin and alogliptin — is also approved); bortezomib, with dexamethasone, to treat adults with progressive multiple myeloma who have received at least one previous treatment and for whom haematopoietic stem ...

  • AWMSG decisions Subscription

    2 OCT 2014 12:12

    The following medicines have not been recommended for use by the All Wales Medicines Strategy Group (AWMSG) and should not be prescribed in NHS Wales: Abiraterone (Zytiga) with prednisolone for metastatic castration-resistant prostate cancer in men who are asymptomatic or mildly symptomatic after androgen deprivation therapy (the drug is allowed for patients whose disease has progressed — as per National Institute ...

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.